Objectives-To evaluate the impact on breast cancer detection from screening breast sonography performed in women with mammographically dense breasts.
A cross the country, states continue to adopt breast density legislation at a high rate. At the time of this writing, 28 states, or more than 50% of states, have passed state laws requiring that patients be informed of their breast density. This widespread adoption has been largely based on several factors, including the inherent increased breast cancer risk for a woman with dense breast tissue, reported to be as high as 4.7-fold compared to a woman with fatty breast tissue. 1 Cancers detected in women with dense breast tissue tend to be larger and more often node positive. 2 Along with notification of the tissue type, most laws also require that the woman be informed that dense breast tissue may be a risk factor for breast cancer, and additional screening services may be beneficial. Although no specific method is mandated by the laws, and with nearly half of American women having dense breasts, 3 this topic is important to address.
As states continue to adopt notification legislation, the most optimal way to offer additional screening to these patients continues to be investigated. Although mammography has been shown to detect breast cancers and reduce mortality, it has been established that the technology has reduced sensitivity in dense breast tissue: reportedly 47.8% to 64.4%. 4 Even in fatty breasts, mammography can miss approximately 12% to 22% of breast cancers. [5] [6] [7] In a recent publication, this population was described perfectly: "they have the 'perfect storm' of decreased mammographic sensitivity and increased risk of breast cancer." 8 Other modalities have been shown to have improved performance over mammography in evaluating dense breast tissue. Several studies have proven that screening sonography can detect early-stage breast cancers in patients with dense breast tissue that is occult on mammography. [9] [10] [11] [12] [13] [14] [15] Breast magnetic resonance imaging is increasingly used in the high-risk population because of its high sensitivity; however, those with dense breast tissue are considered to be at moderate risk, and thus it is difficult to get insurance approval for magnetic resonance imaging screening in this population.
Our facility has been notifying patients of their breast density since January 1, 2013, and providing screening breast sonography for those who request it. We previously published our preliminary data, which showed a slow uptake for those patients seeking additional screening with sonography. We have continuously collected data on this cohort to evaluate the performance of screening sonography in women with dense breast tissue, which includes heterogeneously dense and extremely dense breasts. The purpose of this study was to evaluate the impact on breast cancer detection from screening breast sonography performed in women with mammographically dense breasts.
Materials and Methods
This study, under Institutional Review Board approval with a waiver of informed consent, used a retrospective electronic chart review. We reviewed all appointments that were scheduled at our facility for screening breast sonography due to notification of dense breast tissue. We excluded those who presented with a symptom at the time of screening sonography and those who at the time of presentation were determined to have scattered or fatty replaced breast tissue density.
Data were collected from January 1, 2013 (the start of the New York State mandate), through August 31, 2015. During this study period, there were a total of 195,982 screening mammographic examinations performed at our facility. Mammography at our facility is performed with either a Selenia LoRad or Dimensions unit (Hologic, Inc, Danbury, CT). Of these, 83,234 patients (42.5%) were informed that their breast tissue was heterogeneously dense or extremely dense. Breast density was assessed on the screening mammogram by the interpreting radiologist using the VolparaDensity system (Volpara Solutions Ltd, Wellington, New Zealand). We evaluated those patients who were notified of their dense breast tissue and had a screening breast sonographic examination performed at our facility. During the study period, there was 5434 screening sonographic examinations performed in 4898 women with heterogeneously dense or extremely dense tissue. Sonographic examinations were performed with either an iU22 (Philips Healthcare, Bothell, WA) or Acuson S2000 (Siemens Medical Solutions, Malvern, PA) system.
We also collected information on patient risk factors. Risk factors collected included personal history of breast or ovarian cancer, family history of breast or ovarian cancer (first, second, and third-degree family members were recorded), prior benign or atypical biopsy results, prior thoracic irradiation (ie, mantle radiation), personal history of an HBOC (hereditary breast and ovarian cancer) gene mutation, family member with a known HBOC mutation, or known Ashkenazi Jewish ancestry. First-degree family relatives included parents, full siblings, and children; second-degree relatives included grandparents, grandchildren, aunts, uncles, nephews, nieces, and half-siblings; and third-degree relatives included first cousins, great grandparents, and great grandchildren. Our facility has a high-risk patient identification program in which we flag patients as potentially high risk based on designated criteria from the National Comprehensive Cancer Network guidelines. During the same period of this study, 25% of our dense tissue screening population was identified as high risk. Of all patients presenting for screening, 26% were flagged as having additional risk factors.
Patients are notified at the time of screening mammography of their breast density. Methods of notification at our facility, as well as standard-of-care procedures, have been previously reported. 15 As patients having screening sonography were also having screening mammography (either the same day or within the same year), we decided to specifically review these cases to determine those with negative mammographic findings and findings on sonography only. The data that were collected included total number of screening mammograms, total number of dense breast screening sonograms, total number of procedures performed, biopsy results, and demographic data. The positive predictive value (PPV), biopsy rate, and cancer detection rate were determined.
Results
Demographics for the 4898 patients in this population are shown in Table 1 . The average patient age was 55.8 years. The average time between mammography and screening sonography was 24 days. Most (67%) of the population undergoing screening sonography was found to have additional risk factors, and 33% reported no risk factors. Of those with a family history of breast cancer (2717), 49.4% (1341) had an affected first-degree relative, 43.3% a second-degree relative, and 7.3% a thirddegree relative.
Most (5198 of 5434 [95.7%]) of the screening sonographic examinations resulted in an American College of Radiology Breast Imaging Reporting and Data System (BI-RADS) category 1 or 2 designation, including 1 case in which category 0 was initially assigned, and after further evaluation a final BI-RADS category of 2 was given. BI-RADS category 3 was assigned in 101 cases, 94 of which had findings on sonography only. Four of these BI-RADS 3 lesions had tissue sampling with core needle biopsy or fine-needle aspiration at follow-up, thus resulting in a BI-RADS 4 designation; 1 was by patient election, and 3 were based on the radiologist's discretion. All 4 had benign pathologic results. The remainder were found to be stable at follow-up; 1 patient did not return to our facility and was considered lost to follow-up.
There were 134 suspicious findings (BI-RADS 4 or 5) in 134 patients; all were recommended for tissue sampling by core needle biopsy, fine-needle aspiration cytology, or surgical excision: 100 were findings on sonography only; 99 of these were histologically sampled, and 1 was directed to surgical excision. Pathologic results revealed benign findings in 79 (79%), atypical findings in 3 (3%; Table 2 ) and malignancy in 18 (18%). All malignancies diagnosed were invasive (including 1 metastatic carcinoma; Table 3 ). Malignant lesions diagnosed were in patients with an average age of 63.6 years. Most (15 of 18 [83%]) had additional risk factors, including a personal or family history of breast or ovarian cancer (Table 4) . One patient did not undergo surgical excision because of extensive metastatic disease. Of the remaining 17, 4 (23.5%) had positive lymph nodes. Tumor grades and sizes are reported in Table 5 . The overall PPV of biopsy was 18.0%, with a 10 an estimate for the incremental cancer detection rate of screening sonography was 2 to 3 per 1000, with a low PPV of 6% to 7%. Other reports have shown a PPV range of 6.6% to 19%. 10, 16, 17 However, the Institute for Clinical and Economic Review report also estimated that the recall rate was at least twice as high as that of mammography, with the biopsy rate likely 3 times as high. 5 We did not have similar findings in our cohort, as we found a low biopsy rate (2.0%), and a higher PPV (18.0%). Our prior report found a slightly higher biopsy rate (2.6%) and a lower PPV of 8%. The results from ACRIN 6666 revealed that the cancer detection rate was 3 or 4 per 1000, 10 which is comparable with our current study results (3.3 per 1000) and has been reported by many other publications to date.
One of the harms frequently cited regarding screening breast sonography is the high recall and biopsy rates. Studies have reported a range of biopsy rates: Kolb et al, 4 2.4%; and Berg et al, 10 8.1%. In our evaluation, we found a low biopsy rate for sonographically detected findings: 2.0% as reported in this study. The cancers found by screening sonography have been reported to be small and node negative (early stage). 10, 14, 18 We found the same to be true for most of the cancers detected in this study, as 44% were 1 cm or smaller, and 78% had negative lymph nodes.
We found that a high percentage (66.7%) of patients pursuing screening sonography at our facility had additional self-reported risk factors (Figures 1 and  2 ). This factor has been a consistent trend, as we saw it with our initial report, in which we found that 68% of the population reported 1 or more risk factors. As mentioned previously, we did find that during the same period of this study, 25% of our screening population with dense tissue was identified as high risk. Of all patients presenting for screening at our facility, 26% were flagged as having additional risk factors. When specifically looking at those with a family history, most had a first-degree family member(s) affected. This finding was different from many of the published reports to date. Hooley et al 14 assessed the risk status of patients, categorizing risk as unknown, none or weak (aunt, grandmother, or cousin with breast cancer), intermediate (postmenopausal mother or sister with breast cancer), or high or very strong (premenopausal mother or sister, multiple premenopausal first-degree relatives, or BRCA positive). Our findings differed in that 65.7% of the study cohort of Hooley et al 14 was found to be low or average risk. Although we did evaluate risk differently, this finding was still telling, as it demonstrates that a greater proportion of our population reported risk factors than those in the study by Hooley et al. 14 Other screening sonographic evaluations have similarly had lower-risk patients. Parris et al 19 reported on family history, which consisted of any family history, and found that 42% of the population pursuing screening sonography after passage of the law had a family history. The ACRIN 6666 trial specifically evaluated women at elevated risk: risk factors included personal history of breast cancer; lifetime risk of 25% or higher by the Gail or Claus model; 5-year Gail model risk; atypical ductal hyperplasia, atypical lobular hyperplasia, lobular carcinoma in situ, or atypical papilloma; BRCA1 or BRCA2 gene mutation; and chest, mediastinal, or axillary irradiation. The ACRIN trial found an increased cancer yield by adding a single screening sonographic examination to mammography in this high-risk patient population, with an additional 1.1 to 7.2 cancers per 1000. Our findings fall in this range.
We noted that the time between screening mammography and screening sonography decreased, as in this study, we found an average of 24 days, with 71% (3881) on the same day. Our prior report found an average of 65 days, with most (87%) performed on a different day. 15 This finding was likely due to our recall protocol for these patients. We make every effort to schedule patients so that at their next annual screening, they are scheduled for both screening mammography and screening sonography, if the patient and her referring physician request. This protocol has taken 3 years to implement, with continued education of the health care providers and the patients regarding breast density and the benefits of additional screening. Additionally, we contact all patients with dense tissue who do not have a screening sonography appointment scheduled before their screening mammography appointment to provide information regarding breast density and the option of screening sonography. This extra outreach for patient education has proved to be beneficial, as shown by the increase in screening sonographic examinations.
There were limitations to this study. As demonstrated in our results, there was a large population of patients with dense tissue pursuing screening sonography who also had additional risk factors. When comparing with our general screening population, we did note that the rate of patients with additional risk factors was quite a bit higher in the population undergoing screening sonography. This factor may have led to a subselection bias. Although we offered screening sonography services to all patients in our screening population identified as having dense breast tissue, those with additional risk factors may have been more inclined to pursue further screening, which could also have had an impact on our study results, as our cancer detection rate could have been higher because of the higher-risk patients.
We found a large increase in appointments for screening sonography in this patient population in the years after implementation of the New York State mandate (459% increase; Figure 3 ). We believe that this finding was likely due to an increase in dissemination of the information regarding breast density and risk in the community. We continue to collect data on this cohort, and we have seen the annual numbers continue to increase. Recently, the New York State governor signed legislation to, among other things, amend the insurance law in relation to coverage for the detection of breast cancer. This amendment was scheduled to go into effect on January 1, 2017. The legislation would prohibit cost sharing for mammographic screening services in any policy that provides hospital surgical or medical care coverage. It further states it would prohibit cost sharing for screening and diagnostic imaging, including diagnostic mammography, breast sonography, and magnetic resonance imaging. It is the expectation that once this legislation goes into effect, there will be a drastic increase in women seeking additional screening services, such as screening sonography. This bill was passed in an attempt to aid individuals seeking screening services by removing the financial barrier.
Our continued experience has shown many benefits of performing screening breast sonography in patients with dense breasts. From our initial report to this report, we can see an increase in the cancer detection rate and PPV and a decrease in the biopsy rate. These findings are important and relevant to discuss, as more facilities begin to implement screening sonography programs. The results from our program continue to demonstrate that the modality can detect otherwise occult breast cancers in women with heterogeneously dense or extremely dense breast tissue.
